KARO BIO’S NOMINATING COMMITTEE FOR THE ANNUAL GENERAL MEETING 2010 APPOINTED

STOCKHOLM, SWEDEN, November 10, 2009. Karo Bio (Reuters: KARO.ST) today announced that a nominating committee for the Annual General Meeting 2010 has been appointed.

In accordance with principles for appointment of a nominating committee resolved by the Annual General Meeting 2009, the following persons, together with the chairman of the board Leon E. Rosenberg, have been appointed to be members of the nominating committee for the Annual General Meeting 2010: Bengt Belfrage (Nordea), Ragnhild Wiborg (Concepio), Thomas Josefsson (Borås Postorder) and Johan Claesson (CA Fastigheter). Shareholders can submit proposals to the nominating committee at the following address: Nominating Committee, Karo Bio AB, Novum, S-141 57 Huddinge, Sweden. The nominating committee’s proposal will be published at the latest in connection with the notice for the Annual General Meeting. The term of office of the nominating committee runs until a new nominating committee has been appointed in accordance with the resolution on appointment of the nominating committee by the Annual General Meeting 2010. For more information please contact: Per Olof Wallström, President Tel: +46 8 608 60 20 E-mail: p.o.wallstrom@karobio.se Erika Söderberg Johnson, CFO and responsible for Investor Relations Tel: +46 8 608 60 52 E-mail: erika.soderberg.johnson@karobio.se About Karo Bio Karo Bio is a drug discovery and development company specializing in endocrinology and targeting nuclear receptors as target proteins for the development of novel pharmaceuticals. The company has a project portfolio with innovative molecules that primarily target dyslipidemia, CNS-disorders, inflammation, and women’s health. In these areas, there are significant market opportunities and a clear need for pharmaceuticals with new mechanisms of action. Karo Bio develops compounds aimed at treating broad patient populations up to clinical proof of concept before out-licensing. In therapeutic niche areas, Karo Bio has the capacity to bring selected compounds into late stage clinical development and, potentially, to the market. In addition to the proprietary projects, Karo Bio has three strategic collaborations with international pharmaceutical companies for development of innovative therapies for the treatment of common diseases. Karo Bio is listed on NASDAQ OMX Stockholm since 1998 (Reuters: KARO.ST). This press release is also available online at: www.karobio.com and www.newsroom.cision.com